The development of BIV and Zika vaccines are key public health priorities identified by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) in the United States.
Imutex will collaborate with the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate development of both vaccines this year (2016). Depending upon the outcomes of these studies, Imutex may also pursue Fast Track designation for these vaccines. The current plan is to commence soonest in 2016:
- Phase II clinical study of universal flu vaccine in the hVIVO and NIAID platforms
- Zika vaccine Phase I clinical study in partnership with the National Institutes of Health (NIH) in Bethesda, Md.